论文部分内容阅读
目的观察卡维地洛对动脉粥样硬化大鼠主动脉谷胱甘肽-S-转移酶Mu1(glutathione S-transferase Mu1,GSTM1)表达的影响,探讨卡维地洛抗动脉粥样硬化的作用机制。方法实验分为正常对照组、动脉粥样硬化模型组、卡维地洛治疗组(卡维地洛10mg/kg.d,连续灌胃6周)。实验结束后,观察大鼠血管形态学变化,检测血清超氧化物歧化酶(SOD)、丙二醛(MDA)含量,观察大鼠主动脉GSTM1表达及活性的变化。结果与正常组比较,动脉粥样硬化模型组血清SOD活性降低,MDA含量增加;与动脉粥样硬化模型组比较,卡维地洛治疗组血清SOD活性明显升高,血清MDA含量明显下降。GSTM1的表达及活性在动脉粥样硬化模型组显著降低,而卡维地洛显著增加了GSTM1的表达及活性。结论卡维地洛具有明显的抗动脉粥样硬化作用,这可能与其增加GSTM1表达,从而增强抗氧化作用,消除氧化应激有关。
Objective To observe the effect of carvedilol on the expression of Glutathione S-transferase Mu1 (GSTM1) in the aorta of atherosclerosis rats and to explore the effect of carvedilol on atherosclerosis mechanism. Methods The experiment was divided into normal control group, atherosclerosis model group and carvedilol treatment group (carvedilol 10mg / kg.d, continuous gavage for 6 weeks). At the end of the experiment, the morphological changes of blood vessels in rats were observed. The levels of serum superoxide dismutase (SOD) and malondialdehyde (MDA) were measured to observe the changes of GSTM1 expression and activity in the aorta of rats. Results Compared with the normal group, serum SOD activity and MDA content in the atherosclerotic model group were increased. Compared with the atherosclerosis model group, the serum SOD activity in the carvedilol treatment group was significantly increased and the serum MDA level was significantly decreased. The expression and activity of GSTM1 were significantly decreased in the atherosclerotic model group, while carvedilol significantly increased the expression and activity of GSTM1. Conclusion Carvedilol has obvious anti-atherosclerotic effect, which may be related to its increasing GSTM1 expression, thereby enhancing the anti-oxidative effects and eliminating oxidative stress.